Haematology 2018

ROBUST Clinical Study Design: Phase III double blind

6 x R-CHOP21 + Lenalidomide 15 mg x 14* n=280

ABC

R

6 x R-CHOP21 + Placebo x 14* n=280

Select by GEP

DLBCL

* Option for 2 additional rituximab doses after completing treatment regimen (if considered standard of care per local practice )

GCB, unclassified

Ineligible

▪ Newly diagnosed DLBCL of ABC type ▪ IPI ≥ 2; ECOG PS ≤ 2; Age 18–80 ▪ Primary Endpoint = PFS ▪ N = 560

ClinicalTrials.gov.NCT02285062